New deal for "OpenAI" to boost AI use in pharmaceutical research

OpenAI announced its acquisition of Orchestra Bio, a company specializing in AI tools for pharmaceutical research, aiming to accelerate the development of new treatments. The company will integrate its technologies with its research toolkit "Rosalind." The financial value of the deal was not disclosed.

OpenAI announced on Tuesday its acquisition of Orchestra Bio, a company specializing in developing AI tools for managing pharmaceutical research programs, in a move aimed at expanding the use of its technologies in the biotechnology sector and accelerating the development of new treatments. The company will integrate Orchestra Bio's team and technologies with its research toolkit "Rosalind," designed to assist scientists in the fields of biology and chemistry, enabling the combination of scientific data analysis with managing the various stages of drug development. According to Axios, the financial value of the deal was not disclosed, while OpenAI confirmed the completion of the process in an official statement published on October 20, 2026. Orchestra Bio announced its joining the company about four years after its founding, during which it developed a platform that helps biotechnology and pharmaceutical companies organize their research programs and manage related operations. The company seeks to expand the role of artificial intelligence from data analysis and suggesting experiments to coordinating work between scientific and administrative teams responsible for drug development.